Skip to main content
Dominick Angiolillo, MD, Cardiology, Jacksonville, FL, UF Health Jacksonville

DominickJosephAngiolilloMD

Cardiology • Jacksonville, FL

Adult Congenital Heart Disease, Interventional Cardiology

Professor of Medicine, University of Florida College of Medicine

Join to view full profile

Dr. Angiolillo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Angiolillo's full profile

Already have an account?

Summary

  • DOMINICK J. ANGIOLILLO, MD, PHD, FACC, FESC, FSCAI is a Professor of Medicine with Tenure status at the University of Florida. He is also the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Dr. Angiolillo is triple board certified by the American Board of Internal Medicine (Internal Medicine, Cardiovascular Disease, Interventional Cardiology). Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. Since 2014 he has been in the top 1 percent of most-cited researchers worldwide according to Clarivate Analytics (formerly Thomson Reuters’ list of The World’s Most Influential Scientific Minds). Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as textbooks of cardiovascular medicine. His leadership role as an academic clinician scientist has allowed to him to nurture and promote career growth and development of many young trainees pursuing both academic and clinical careers in the United States and abroad. Dr. Angiolillo is an active member of many cardiovascular societies in the Unites States and Europe.

Education & Training

  • University of Florida
    University of FloridaFellowship, Cardiovascular Disease, 2004 - 2007
  • University of Cattolica del Sacro Cuore
    University of Cattolica del Sacro CuoreClass of 1997

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2007 - 2025
  • American Board of Internal Medicine Cardiovascular Disease
  • American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Reply P2Y12 Inhibitor–Based Monotherapy: Optimal Duration and Ideal Agent  
    Dominick Angiolillo, MD, JACC: Cardiovascular Imaging
  • Coronary Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography  
    Somjot Brar, Hitinder S Gurm, Barry Bertolet, Anand Prasad, Dominick J Angiolillo, Roxana Mehran, George Dangas, Wayne Batchelor, Gregg W Stone, ScienceDirect
  • Research Letter Ticagrelor Versus Clopidogrel for Recovery of Vascular Function Immediately After Successful Chronic Coronary Total Occlusion Recanalization: A Randomi...  
    Dominick Angiolillo, MD, ScienceDirect
  • Join now to see all

Lectures

  • Take Home for Clinicians: DM and STEMI 
    CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
  • Cardioprevention in Primary Care: Where Does Aspirin Fit In? 
  • Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective 
    2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
  • Join now to see all

Authored Content

  • Reply P2Y12 Inhibitor–Based Monotherapy: Optimal Duration and Ideal AgentSeptember 2020
  • Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
  • Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
  • Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
  • Pharmacogenomic Testing to Select Antiplatelet TherapyApril 2018
  • High on-Treatment Platelet Reactivity and Outcome in Elderly with Non ST-Segment Elevation Acute Coronary Syndrome - Insight from the GEPRESS StudyMarch 2018
  • The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCIMarch 2018
  • Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
  • Join now to see all

Press Mentions

  • Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5
    Cangrelor After Ticagrelor Pretreatment in ACS Might Be OK: SWAP-5November 11th, 2022
  • Some Needs Unmet in Secondary CVD Prevention Despite Aspirin Use; New Agent May Have Role
    Some Needs Unmet in Secondary CVD Prevention Despite Aspirin Use; New Agent May Have RoleMay 12th, 2022
  • Impact of Age Examined for Ticagrelor Monotherapy After PCI
    Impact of Age Examined for Ticagrelor Monotherapy After PCIJuly 8th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Dominick Angiolillo, Dr. Dominick Angiolillo, MD, Dr. D Angiolillo, Dr. Dominick Joseph Angiolillo